Paratek Pharms Drug Patent Portfolio
Paratek Pharms owns 2 orange book drugs protected by 31 US patents Given below is the list of Paratek Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10383884 | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) | 31 Oct, 2037 | Active |
| US10835542 | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) | 31 Oct, 2037 | Active |
| US10111890 | 9-aminomethyl minocycline compounds and uses thereof | 03 Aug, 2037 | Active |
| US11554229 | Nasal administration | 23 Feb, 2036 | Active |
| US10300229 | Nasal delivery devices | 07 Jul, 2035 | Active |
| US10076614 | Nasal delivery devices | 20 Oct, 2034 | Active |
| US10478574 | Nasal administration | 04 Nov, 2033 | Active |
| US10179216 | Nasal delivery devices | 08 Jul, 2033 | Active |
| US11033696 | Nasal delivery devices | 20 May, 2033 | Active |
| US12083270 | Delivery device and method | 04 Apr, 2031 | Active |
| US9314475 | Oral and injectable formulations of tetracycline compounds | 18 Mar, 2031 | Active |
| US10252010 | Nasal delivery devices | 07 Feb, 2031 | Active |
| US8978647 | Nasal delivery | 06 Dec, 2030 | Active |
| US9265740 | Minocycline compounds and methods of use thereof | 24 Oct, 2030 | Active |
| US8383610 | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline | 23 Sep, 2030 | Active |
| US8550073 | Nasal delivery | 22 Oct, 2029 | Active |
| US10076615 | Nasal delivery | 30 Jul, 2029 | Active |
| US10124014 | Minocycline compounds and methods of use thereof | 05 Mar, 2029 | Active |
| US9724358 | Minocycline compounds and methods of use thereof | 05 Mar, 2029 | Active |
| US11602603 | Nasal delivery devices | 27 Oct, 2028 | Active |
| US10124132 | Nasal delivery | 06 Mar, 2027 | Active |
| US7975690 | Nasal devices | 29 Dec, 2025 | Expired |
| US7553828 | 9-aminomethyl substituted minocycline compounds | 02 Jun, 2025 | Expired |
| US8522778 | Nasal devices | 20 Apr, 2024 | Expired |
| US8327844 | Nasal delivery method | 24 Oct, 2023 | Expired |
| US7326696 | Amino-methyl substituted tetracycline compounds | 24 Sep, 2023 | Expired |
| US9365500 | 9-aminomethyl substituted minocycline compounds | 29 Jun, 2021 | Expired |
| US9072857 | Nasal delivery device | 10 Apr, 2021 | Expired |
| US6715485 | Nasal delivery device | 03 Sep, 2020 | Expired |
| US9468727 | Nasal delivery | 30 Jul, 2020 | Expired |
| US8555878 | Nasal delivery device | 20 Mar, 2020 | Expired |
Latest Legal Activities on Paratek Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Paratek Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 10 Jun, 2024 | US9468727 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 May, 2024 | US10835542 |
|
Interim Patent Term Extension Granted
Critical
| 13 May, 2024 | US7553828 |
| Court Processing Terminated | 17 Apr, 2024 | US7553828 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2024 | US7553828 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US7553828 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Oct, 2023 | US9314475 |
|
Expire Patent
Critical
| 14 Aug, 2023 | US9072857 |
|
Recordation of Patent Grant Mailed
Critical
| 14 Mar, 2023 | US11602603 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 14 Mar, 2023 | US11602603 |
|
Maintenance Fee Reminder Mailed
Critical
| 27 Feb, 2023 | US9072857 |
|
Email Notification
Critical
| 23 Feb, 2023 | US11602603 |
|
Issue Notification Mailed
Critical
| 22 Feb, 2023 | US11602603 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Feb, 2023 | US10383884 |
| Second letter to regulating agency to determine regulatory review period | 17 Feb, 2023 | US7553828 |
Paratek Pharms Drug Patents' Oppositions Filed in EPO
Paratek Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 27, 2005, by Direct-Haler A/S. This opposition was filed on patent number EP00906570A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17190469A | Aug, 2021 | Beck Greener LLP | Granted and Under Opposition |
| EP08736896A | Jun, 2021 | Beck Greener LLP | Patent maintained as amended |
| EP18158017A | May, 2021 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP13715145A | Sep, 2020 | ELKINGTON AND FIFE LLP | Granted and Under Opposition |
| EP00906570A | Sep, 2005 | Direct-Haler A/S | Opposition rejected |
Paratek Pharms's Family Patents
Paratek Pharms drugs have patent protection in a total of 44 countries. It's US patent count contributes only to 20.1% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Paratek Pharms Drug List
Given below is the complete list of Paratek Pharms's drugs and the patents protecting them.
1. Nuzyra
Nuzyra is protected by 12 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10383884 | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
31 Oct, 2037
(11 years from now)
| Active |
| US10835542 | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
31 Oct, 2037
(11 years from now)
| Active |
| US10111890 | 9-aminomethyl minocycline compounds and uses thereof |
03 Aug, 2037
(11 years from now)
| Active |
| US9314475 | Oral and injectable formulations of tetracycline compounds |
18 Mar, 2031
(5 years from now)
| Active |
| US9265740 | Minocycline compounds and methods of use thereof |
24 Oct, 2030
(4 years from now)
| Active |
| US8383610 | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
23 Sep, 2030
(4 years from now)
| Active |
| US10124014 | Minocycline compounds and methods of use thereof |
05 Mar, 2029
(3 years from now)
| Active |
| US9265740 | Minocycline compounds and methods of use thereof |
05 Mar, 2029
(3 years from now)
| Active |
| US9724358 | Minocycline compounds and methods of use thereof |
05 Mar, 2029
(3 years from now)
| Active |
| US7553828 | 9-aminomethyl substituted minocycline compounds |
02 Jun, 2025
(6 months ago)
| Expired |
| US7326696 | Amino-methyl substituted tetracycline compounds |
24 Sep, 2023
(2 years ago)
| Expired |
| US9365500 | 9-aminomethyl substituted minocycline compounds |
29 Jun, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nuzyra's drug page
2. Xhance
Xhance is protected by 20 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11554229 | Nasal administration |
23 Feb, 2036
(10 years from now)
| Active |
| US10300229 | Nasal delivery devices |
07 Jul, 2035
(9 years from now)
| Active |
| US10076614 | Nasal delivery devices |
20 Oct, 2034
(8 years from now)
| Active |
| US10478574 | Nasal administration |
04 Nov, 2033
(7 years from now)
| Active |
| US10179216 | Nasal delivery devices |
08 Jul, 2033
(7 years from now)
| Active |
| US11033696 | Nasal delivery devices |
20 May, 2033
(7 years from now)
| Active |
| US12083270 | Delivery device and method |
04 Apr, 2031
(5 years from now)
| Active |
| US10252010 | Nasal delivery devices |
07 Feb, 2031
(5 years from now)
| Active |
| US8978647 | Nasal delivery |
06 Dec, 2030
(4 years from now)
| Active |
| US8550073 | Nasal delivery |
22 Oct, 2029
(3 years from now)
| Active |
| US10076615 | Nasal delivery |
30 Jul, 2029
(3 years from now)
| Active |
| US11602603 | Nasal delivery devices |
27 Oct, 2028
(2 years from now)
| Active |
| US10124132 | Nasal delivery |
06 Mar, 2027
(1 year, 2 months from now)
| Active |
| US7975690 | Nasal devices |
29 Dec, 2025
(2 days ago)
| Expired |
| US8522778 | Nasal devices |
20 Apr, 2024
(1 year, 8 months ago)
| Expired |
| US8327844 | Nasal delivery method |
24 Oct, 2023
(2 years ago)
| Expired |
| US9072857 | Nasal delivery device |
10 Apr, 2021
(4 years ago)
| Expired |
| US6715485 | Nasal delivery device |
03 Sep, 2020
(5 years ago)
| Expired |
| US9468727 | Nasal delivery |
30 Jul, 2020
(5 years ago)
| Expired |
| US8555878 | Nasal delivery device |
20 Mar, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xhance's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List